Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

5 terminated/withdrawn out of 10 trials

Success Rate

16.7%

-69.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

3 recruiting4 withdrawn

Enrollment Performance

Analytics

Phase 1
9(90.0%)
Phase 2
1(10.0%)
10Total
Phase 1(9)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT04853329Phase 1Terminated

Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

Role: lead

NCT07424547Phase 1Recruiting

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Role: lead

NCT05948865Phase 1Recruiting

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

Role: lead

NCT07317505Phase 1Recruiting

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

Role: lead

NCT04931823Phase 1Active Not Recruiting

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Role: lead

NCT05043987Phase 1Withdrawn

Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers

Role: lead

NCT04675450Phase 2Withdrawn

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

Role: lead

NCT03657550Phase 1Completed

Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

Role: lead

NCT03567694Phase 1Withdrawn

Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers

Role: lead

NCT03553914Phase 1Withdrawn

PLM60 for Peripheral T Cell Lymphoma (PTCL)

Role: lead

All 10 trials loaded